Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M12.5Revenue $M4.4Net Margin (%)-433.1Altman Z-Score-35.5
Enterprise Value $M11.8EPS $-7.0Operating Margin %-479.7Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.8Pre-tax Margin (%)-432.8Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio0.7Cash flow > EarningsY
Price/Sales1.65-y EBITDA Growth Rate %16.9Current Ratio1.0Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-252.1Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-2,354.0Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M5.0ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with NBY

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

NBY is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


NBY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Najafi RaminCEO, 10% Owner 2015-08-20Buy480$11.75-78.72view
Pioneer Pharma (Singapore) Pte10% Owner 2015-03-03Buy103,600$15-83.33view
SIECZKAREK MARK MDirector 2015-03-03Buy6,667$15-83.33view
Najafi RaminChairman 2015-03-03Buy6,667$15-83.33view
Najafi RaminChairman 2014-12-12Buy2,000$16.25-84.62view
PAULSON THOMAS JCFO 2014-12-12Buy400$17-85.29view
Stroman David W.SVP, Ophthalmic Product Devt. 2014-12-12Buy400$16.5-84.85view
Najafi RaminChairman 2014-12-11Buy800$15-83.33view
PAULSON THOMAS JCFO 2014-12-09Buy400$16.75-85.07view
Najafi RaminChairman 2014-12-05Buy1,000$16.25-84.62view

Press Releases about NBY :

Quarterly/Annual Reports about NBY:

News about NBY:

Articles On GuruFocus.com
NovaBay Pharmaceuticals Inc. (NBY) Chairman Ramin Najafi buys 1,000 Shares Aug 28 2009 

More From Other Websites
NovaBay Says Its Avenova Cuts Bacteria On Ocular Skin Surface By Over 90% May 03 2016
Clinical Data Presented at ARVO Showing NovaBay’s Avenova Reduces Bacteria on Ocular Skin Surface... May 03 2016
7:02 am NovaBay Pharma announces the presentation of clinical data demonstrating that Avenova... May 03 2016
Clinical Data Presented at ARVO Showing NovaBay’s Avenova Reduces Bacteria on Ocular Skin Surface... May 03 2016
[$$] NovaBay Not Seen Breaking Even for Years Apr 07 2016
NovaBay Pharmaceuticals Announces Agreement for Nearly $12 Million in Two-Tranche Private Placement Apr 06 2016
NovaBay Pharmaceuticals Announces Agreement for Nearly $12 Million in Two-Tranche Private Placement Apr 06 2016
NovaBay Pharmaceuticals Announces Filing of Annual Report on Form 10-K Mar 22 2016
NovaBay Pharmaceuticals Announces Filing of Annual Report on Form 10-K Mar 22 2016
NovaBay Pharmaceuticals to Present at 28th Annual ROTH Conference Mar 08 2016
NovaBay Pharma downgraded by Maxim Group Mar 07 2016
NovaBay Pharmaceuticals Reports 2015 Fourth Quarter and Full Year Financial Results Mar 03 2016
NovaBay Pharmaceuticals to Hold 2015 Fourth Quarter and Full Year Conference Call on March 3 Feb 25 2016
NovaBay Pharmaceuticals Announces $2.83 Million Private Placement Feb 24 2016
NovaBay Pharmaceuticals Expects Fourth Quarter 2015 Avenova Sales to Exceed $1.5 Million Jan 11 2016
NovaBay Pharmaceuticals Expects Fourth Quarter 2015 Avenova Sales to Exceed $1.5 Million Jan 11 2016
3 Biotech Stocks Under $10 to Trade for Big Breakouts Jan 08 2016
NovaBay Pharmaceuticals Secures $3 Million Bridge Loan Jan 07 2016
NovaBay Pharmaceuticals Secures $3 Million Bridge Loan Jan 07 2016
NOVABAY PHARMACEUTICALS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change... Dec 21 2015

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)